MME and diffuse large B-cell lymphoma: Over the years, immunohistochemical markers have been established to discriminate individual DLBCL subgroups and several of them—CD10, BCL‐6, MUM1, BCL‐2, and CYCLIN D1—have been associated with clinical outcome.